La cadena de opciones muestra datos clave de las opciones de acciones de Aethlon Medical a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Aethlon Medical..

Aethlon Medical (NASDAQ:AEMD) Bolsa, Cadena de Opciones

Aethlon Medical

Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

LITM

MESO

NVNI

PTPI

QNTM

SGMO

SLXN

VRAX

Acciones de Sangamo Therapeutics suben un 19,5% tras un nuevo acuerdo. Descubre los mayores ganadores y perdedores de hoy.

Acciones de Sangamo Therapeutics (SGMO) suben alrededor de un 20%; 20 acciones que se mueven en el premercado

Aethlon Medical Inc

<h3>Gainers</h3>
<ul>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares moved upwards by 376.8% to $3.19 during Thursday's pre-market session. The market value of their outstanding shares is at $13.7 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock rose 50.2% to $18.4. The company's market cap stands at $2.0 billion. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 38.56% to $2.12. The market value of their outstanding shares is at $1.7 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock moved upwards by 35.45% to $1.49. The market value of their outstanding shares is at $76.7 million. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) stock rose 33.78% to $9.98. The company's market cap stands at $578.3 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock rose 26.21% to $4.77. The market value of their outstanding shares is at $10.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 35.1% to $0.43 during Thursday's pre-market session. The market value of their outstanding shares is at $5.9 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock decreased by 26.75% to $2.41. The market value of their outstanding shares is at $10.1 million. </li>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock fell 20.01% to $11.2. The company's market cap stands at $681.5 million. </li>
<li>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) stock decreased by 17.87% to $3.31. The market value of their outstanding shares is at $29.5 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares fell 13.93% to $3.4. The market value of their outstanding shares is at $3.2 million. </li>
<li>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) stock fell 12.85% to $390.0. The market value of their outstanding shares is at $100.4 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BPTH

ISPC

MRKR

MYNZ

OMER

PLRX

PLRZ

VRTX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.47% to 42,525.10 while the NASDAQ rose 0.84% to 19,554.71. The S&amp;P 500 also rose, gaining, 0.62% to 5,908.52.
Check This Out: <a href="https://www.benzinga.com/24/12/42582254/top-3-consumer-stocks-you-may-want-to-dump-this-quarter">Top 3 Consumer Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 1.1% on Thursday.
In trading on Thursday, health care shares fell by 0.7%.
Top Headline
Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) posted better-than-expected earnings for its first quarter, while sales missed expectations.
The company said it sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares shot up 532% to $13.85.</li>
<li>Shares of Trio Petroleum Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NASDAQ">TPET</a>)got a boost, surging 358% to $3.7550 after the company announced it will acquire the oil and gas assets in a heavy oil region of Saskatchewan, Canada for approximately $1.4 million.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares were also up, gaining 281% to $2.55 after the company announced preclinical testing of BP1001-A as a potential treatment for obesity in Type 2 diabetes patients by enhancing insulin sensitivity.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares dropped 61% to $0.3185 as the company reported the pricing of public offering.</li>
<li>Shares of Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) were down 38% to $0.4070.</li>
<li>WANG &amp; LEE GROUP, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) was down, falling 43% to $1.15.</li>
</ul>
Commodities In commodity news, oil traded up 0.3% to $70.78 while gold traded down 1.7% at $2,607.90.
Silver traded down 4.6% to $29.315 on Thursday, while copper fell 1.5% to $4.0955.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 1.7%, Germany's DAX fell 1.3% and France's CAC 40 declined 1.3%. Spain's IBEX 35 Index fell 1.7%, while London's FTSE 100 fell 1.3%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 0.69%, Hong Kong's Hang Seng Index falling 0.56%, China's Shanghai Composite Index declining 0.36% and India's BSE Sensex falling 1.20%.
Economics
<ul>
<li>The Philadelphia Fed Manufacturing Index dipped to -16.4 in December compared to -5.5 in November and down from market expectations of 3.</li>
<li>The U.S. economy grew by an annualized rate of 3.1% in the third quarter compared to 2.8% in the second estimate and up from 3% in the previous quarter.</li>
<li>U.S. existing home sales gained by 4.8% from the previous month to an annualized rate of 4.15 million in November.</li>
<li>U.S. initial jobless claims declined by 22,000 to 220,000 in the first week of December, compared to market estimates of 230,000.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42591599/att-to-rally-more-than-33-here-are-10-top-analyst-forecasts-for-thursday">AT&amp;T To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Thursday</a></li>
</ul>

Eurozone

Commodities

Intraday Update

PRFX

TPET

WLGS

US Stocks Higher, Micron Reports Downbeat Sales

Shares of Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) rose sharply in today's <a href="https://www.benzinga.com/quote/SGMO/news">pre-market trading</a>.
Astellas and Sangamo Therapeutics disclosed Capsid license agreement to deliver genomic medicines for neurological diseases.
Sangamo Therapeutics shares jumped 19.5% to $2.81 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>CURRENC Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) gained 219.5% to $6.39 in pre-market trading after jumping 54% on Wednesday.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) climbed 170% to $2.13 in pre-market trading after declining over 50% on Wednesday.</li>
<li>AppTech Payments Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APCX#NASDAQ">APCX</a>) gained 170% to $1.03 in pre-market trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) gained 68% to $3.55 in pre-market trading after dropping 26% on Wednesday.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 44.5% to $17.70 in pre-market trading. Mesoblast&#8217;s RYONCIL became the first FDA-approved mesenchymal stromal cell therapy in the U.S.</li>
<li>Elevai Labs Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) gained 38.6% to $2.98 in pre-market trading after gaining 9% on Wednesday.</li>
<li>Dallasnews Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) gained 38% to $6.72 in pre-market trading after falling 5% on Wednesday.</li>
<li>KULR Technology Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NASDAQ">KULR</a>) rose 28% to $2.68 in pre-market trading after jumping 44% on Wednesday.</li>
<li>XCHG Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) gained 24.2% to $2.67 in pre-market trading after dipping more than 90% on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares tumbled 40.5% to $0.4847 in pre-market trading after jumping 348% on Wednesday.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) declined 36.4% to $0.42 in pre-market trading after jumping more than 80% on Wednesday.</li>
<li>Abacus Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) shares fell 20.5% to $6.00 in pre-market trading.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) shares dipped 18.6% to $63.50 in pre-market trading as the company posted downbeat quarterly results and lowered FY25 outlook.</li>
<li>Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) fell 18.5% to $0.5213 in today's pre-market trading after jumping 52% on Wednesday.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) dipped 15.6% to $87.60 in pre-market trading. Micron posted better-than-expected earnings for its first quarter, while sales missed expectations. The company said it sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share.</li>
<li>Virax Biolabs Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) fell 15.6% to $2.00 in pre-market trading after surging 39% on Wednesday.</li>
<li>Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) shares fell 14.5% to $2.95 in pre-market trading after dipping 18% on Wednesday.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) fell 14.3% to $0.3008 in pre-market trading following a 30% plunge on Wednesday.</li>
<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) fell 14.2% to $5.10 in pre-market trading after declining 5% on Wednesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42553288/top-3-tech-and-telecom-stocks-that-may-crash-this-month">Top 3 Tech And Telecom Stocks That May Crash This Month</a></li>
</ul>

Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

<a href="https://x.com/leahjdouglas/status/1865080809100582944" title="https://x.com/leahjdouglas/status/1865080809100582944">https://x.com/leahjdouglas/status/1865080809100582944</a>

Biotech

General

NVAX

Reuters Agriculture & Energy Policy Reporter Leah Douglas Posts On X "SCOOP: The USDA is issuing a federal order mandating the national milk supply be tested for bird flu. Testing will begin Dec. 16 in six states: CA, CO, MI, MS, PA, OR. Bird flu has infected nearly half of dairy farms in California, the top milk state."

<a href="https://worldhealthorg.shinyapps.io/mpx_global/" title="https://worldhealthorg.shinyapps.io/mpx_global/">https://worldhealthorg.shinyapps.io/mpx_global/</a>

APDN

CMRX

GOVX

TNXP

World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern

Shares of Tesla, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose sharply in today's pre-market trading after a report on Sunday, suggested that the upcoming regulatory framework might ease <a href="https://www.benzinga.com/markets/equities/24/11/42028797/tesla-soars-over-5-in-overnight-trading-as-trump-administration-reportedly-seeks-to-ease-fsd-norms">mandates for self-driving vehicles</a>.
The transition team of President-elect Donald Trump has told advisors that it aims to make a framework for fully self-driving vehicles a priority for the Transportation Department, reported Bloomberg, citing people familiar with the matter.
Tesla shares jumped 8.2% to $347.13 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Apollomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) gained 80.3% to $0.1725 in pre-market trading after declining 8% on Friday.</li>
<li>Mobile-health Network Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) rose 63% to $0.4238 in pre-market trading after dipping around 12% on Friday.</li>
<li>AtlasClear Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NYSE">ATCH</a>) gained 51.1% to $0.2720 in pre-market trading.</li>
<li>DDC Enterprise Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDC#NYSE">DDC</a>) gained 29.1% to $0.2655 in pre-market trading.</li>
<li>Liberty Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) gained 28% to $21.63 in pre-market trading.</li>
<li>VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>) gained 15.1% to $0.9450 in pre-market trading after dipping 39% on Friday.</li>
<li>Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) climbed 12.7% to $15.75 in pre-market trading after the company said initial Phase 1 data suggesting Nexiguran Ziclumeran, an in vivo CRISPR/Cas9 gene editing therapy, may benefit ATTR Amyloidosis Progression.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) gained 12.7% to $0.45 in pre-market trading.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 11.1% to $20.64 in pre-market trading after gaining more than 3% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) shares tumbled 33.2% to $0.4600 in pre-market trading after gaining around 13% on Friday.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 28.5% to $1.20 in pre-market trading. CareMax reached agreements to sell Management Services Organization and Core Centers&#8217; assets.</li>
<li>Paramount Gold Nevada Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PZG#NYSE">PZG</a>) shares fell 27.8% to $0.3301 in pre-market trading after gaining around 4% on Friday.</li>
<li>QMMM Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) declined 23.4% to $5.61 in pre-market trading after falling 13% on Friday.</li>
<li>The Arena Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AREN#NYSE">AREN</a>) dipped 23.4% to $1.34 in pre-market trading. Arena Group shares jumped 207% on Friday after it announced its first ever profitable quarter.</li>
<li>Siyata Mobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) shares dipped 22.1% to $0.9895 in pre-market trading. Siyata Mobile recently reported better-than-expected third-quarter EPS results.</li>
<li>Eterna Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) fell 15% to $0.7100 in pre-market trading after dipping 12% on Friday.</li>
<li>Cyclerion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) fell 14% to $2.22 in pre-market trading after jumping more than 45% on Friday.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) fell 12.3% to $4.43 in pre-market trading after gaining around 9% on Friday. Kingsoft Cloud will release its unaudited financial results for the third quarter before the opening bell on Nov. 19.</li>
<li>Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) fell 9.3% to $0.8890 in today's pre-market trading after declining around 5% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>

APLM

AREN

ATCH

CMAX

CYCN

ERNA

FLYE

LAZR

LBRT

MNDR

NTLA

QMMM

SMCI

SYTA

TSLA

VVPR

Why Tesla Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) with a Buy and maintains $7 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Aethlon Medical, Maintains $7 Price Target

Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 83.61 percent increase over losses of $(1.22) per share from the same period last year.

Earnings

Aethlon Medical Q2 2025 GAAP EPS $(0.20), Inline

ACXP

ADAP

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CAPR

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) will release its quarterly earnings report on Wednesday, 2024-11-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Aethlon Medical to report an earnings per share (EPS) of $-0.19.
Anticipation surrounds Aethlon Medical's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
In the previous earnings release, the company missed EPS by $0.03, leading to a 16.86% drop in the share price the following trading session.
Here's a look at Aethlon Medical's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.31</td>
<td>-1.23</td>
<td>-1.23</td>
<td>-1.40</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.34</td>
<td>-0.91</td>
<td>-1.37</td>
<td>-1.22</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-17.0%</td>
<td>-14.000000000000002%</td>
<td>-5.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731438218_0.png" alt="eps graph" />
<a href="https://www.benzinga.com/quote/AEMD/earnings">To track all earnings releases for Aethlon Medical visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Aethlon Medical's Earnings

WIIM

Aethlon Medical shares are trading higher after the company announced it enrolled its first patient in its Australian hemopurifier cancer trial targeting patients with solid tumors unresponsive to anti-pd-1 therapy.

Aethlon Medical Enrolls First Patient In Australian Hemopurifier Cancer Trial; Study Targets Patients With Solid Tumors Unresponsive To Anti-PD-1 Therapy

https://www.reuters.com/world/uk/uk-detects-two-more-cases-new-mpox-variant-2024-11-04/#:~:text=LONDON%2C%20Nov%204%20(Reuters),to%20the%20population%20remained%20low.

Macro Notification

MRNA

'UK detects two more cases of new mpox variant' - Reuters

BWVI

WHO Expands Emergency Use List For Mpox Diagnostics, Adds Cepheid's Xpert Mpox PCR Test And Roche's Cobas MPXV Assay As PCR-Based Gold Standard Options

<a href="https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms">https://economictimes.indiatimes.com/news/international/world-news/new-mpox-variant-detected-in-germany-health-authority/articleshow/114463317.cms</a>
An infection with the new mpox variant clade 1b has been detected in Germany for the first time, the Robert Koch Institute health authority said on Tuesday. &nbsp;

Reported Earlier, 'New Mpox Variant Detected In Germany: Health Authority' - The Economic Times

<h3>Gainers</h3>
<ul>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares increased by 51.2% to $0.51 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.6 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock rose 23.64% to $1.83. The company's market cap stands at $136.7 million. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) stock moved upwards by 21.54% to $0.9. The company's market cap stands at $65.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares increased by 18.47% to $1.09. The market value of their outstanding shares is at $1.7 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock increased by 10.83% to $0.44. The market value of their outstanding shares is at $6.1 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) stock rose 10.28% to $0.35. The market value of their outstanding shares is at $26.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock decreased by 11.8% to $0.6 during Wednesday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock fell 11.53% to $0.23. The market value of their outstanding shares is at $1.4 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares decreased by 10.93% to $1.06. The market value of their outstanding shares is at $2.7 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares declined by 9.44% to $1.11. The company's market cap stands at $67.0 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock decreased by 9.31% to $0.58. The market value of their outstanding shares is at $5.8 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock decreased by 7.2% to $2.41. The company's market cap stands at $5.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLSD

CTCX

NIVF

TIVC

WINT

XCUR

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<a href="https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.">https://pasadenanow.com/main/mpox-cases-double-in-los-angeles-county-health-officials-urge-vaccination#:~:text=Los%20Angeles%20County%20health%20officials,the%20previous%20four%2Dweek%20period.</a>
&nbsp;
Los Angeles County health officials are reporting a significant uptick in mpox cases, prompting renewed calls for vaccination among&nbsp;high-risk&nbsp;groups.
The County's Department of Public Health announced that 52 mpox cases were reported in the past four weeks, compared to 24 in the previous&nbsp;four-week&nbsp;period.&nbsp;
About 70% of new cases in the last six months occurred in&nbsp;unvaccinated&nbsp;individuals.
Health officials strongly recommend vaccination for several high-risk groups, including men and transgender people who have sex with men or transgender persons, persons of any gender or sexual orientation who have sex or intimate physical contact with others in association with large public events or engage in commercial and/or transactional sex, and those living&nbsp;with&nbsp;HIV.
"Vaccination is an important tool in preventing the spread of mpox," the County health department said in a statement. The two-dose JYNNEOS vaccine is available at pharmacies for insured residents and at Los Angeles County Department of Public Health Clinics for free&nbsp;without&nbsp;appointments.
Officials advise residents to practice safe sex, limit sexual partners, and avoid intimate contact with anyone showing mpox symptoms, which include rash, fever, and swollen lymph nodes. Additional prevention measures include asking partners about symptoms, reducing the number of partners, and proper use of condoms&nbsp;and&nbsp;gloves.
The County emphasizes the importance of testing for those who develop symptoms consistent with mpox. The Department of Public Health is collaborating with healthcare providers and community organizations to intensify surveillance, contact tracing, and outbreak investigations to&nbsp;curb&nbsp;transmission.
Mpox, previously referred to as Monkeypox, is mainly spread through close physical contact. Residents seeking more information can visit<a href="http://ph.lacounty.gov/mpox"> ph.lacounty.gov/mpox</a> or call the Department of Public Health Call Center&nbsp;at&nbsp;1-833-540-0473.

Macro Economic Events

Economics

'Mpox Cases Double In Los Angeles County, Health Officials Urge Vaccination; Los Angeles County Public Health Officials Report Increase, Recommend Prevention Measures' - Pasadena Now

<a href="https://www.youtube.com/watch?v=ZFW3ONApp4w" title="https://www.youtube.com/watch?v=ZFW3ONApp4w">https://www.youtube.com/watch?v=ZFW3ONApp4w</a>

Biden On Sudan Says End This War Now; Let's Move Quickly To Face Mpox Outbreak In Africa

CDC Says No Cases Of Clade IA Mpox Have Been Reported Outside Central African Countries Where Clade IA MPVX Is Endemic

Aethlon Medical shares are trading higher after the company announced that it received granted ethics committee approval for Hemopurifier cancer treatment. Also, the European Commission recommended extending the indication of the smallpox and mpox vaccine to adolescents.

Aethlon Medical ( ($AEMD) ) just unveiled an update. Aethlon Medical, Inc. has elevated James B. Frakes from Interim to permanent Chief Executive O...

Aethlon Medical Appoints James B. Frakes as CEO

Aethlon Medical (AEMD) announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemop...

Aethlon Medical enrolls first patient in Hemopurifier cancer trial in Australia

Here are the major earnings after the close today

Aethlon Medical GAAP EPS of -$0.20 in-line

As of September 30, 2024, Aethlon Medical (AEMD) had a cash balance of approximately $6.9M. "During Q2 and subsequent period, we continued advancin...

Aethlon Medical reports Q3 EPS (20c) vs. ($1.22) last year

Aethlon Medical ( ($AEMD) ) just unveiled an update. Aethlon Medical, Inc. has reported significant advancements in its oncology trials, enrolling ...

Aethlon Medical Advances Oncology Trials and Global Expansion

Comments

Aethlon Medical

Aethlon Medical (AEMD) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL